Corning Showcases Expanded Drug Discovery Portfolio at SLAS 2014

Image Alt Text

Corning Showcases Expanded Drug Discovery Portfolio at SLAS 2014

Corning Showcases Expanded Drug Discovery Portfoli

News Releases
Life Sciences
Corning Showcases Expanded Drug Discovery Portfolio at SLAS 2014
Corning Showcases Expanded Drug Discovery Portfolio at SLAS 2014
CORNING, N.Y. | Corning Incorporated | 2014年1月17日
New microplates help researchers improve results, save time and resources

Corning Incorporated (NYSE: GLW) today announced its new Corning® 96- and 384-Well Spheroid Microplates and the Corning® High-Content Imaging Cyclic Olefin Copolymer (COC) Microplates. Corning Life Sciences will showcase its latest innovations in booth #1029 at the Society for Laboratory Automation & Screening (SLAS) 2014 Conference, Jan. 18-22, in San Diego, Calif.

The new Corning® Spheroid Microplates feature black, optically clear, round bottoms and the Corning® Ultra-Low Attachment Surface which allows researchers to culture and assay spheroids in the same microplate without having to transfer. These features limit the potential for contamination and save researchers time and resources. The 96- and 384-well plates both have a standard Society for Biomolecular Screening (SBS) footprint and are compatible with existing imagers, readers, liquid handling and automation equipment.  

“Cancer research today requires advanced technologies to accelerate drug discovery while maintaining the highest levels of quality and integrity of results,” said Dr. Keith Olson, business director, Advanced Life Sciences, Corning Life Sciences. “Our new spheroid microplates support this growing trend in primary cell research, providing researchers with all the advanced features and benefits which allow them to generate and analyze 3-D multicellular spheroids in the same microplate, without risk of potential contamination.”

The Corning® High-Content Imaging Cyclic Olefin Copolymer (COC) Microplates feature an ultra-clear film with a thickness of 127 μm and an unprecedented flatness (whole plate and intra-well), making them ideal for high-resolution cellular imaging applications. The microplate and film are manufactured from cyclic olefin copolymer, which has excellent optical properties, and mechanical stability.

Corning Life Sciences’ complete drug discovery offerings also now include a range of products and services to support absorption, distribution, metabolism, and excretion (ADME), and toxicology applications.  This includes the new Corning® TransportoCells™, high- performance mammalian cryopreserved cells that transiently overexpress individual human solute carrier (SLC) transporter proteins. Corning® TransportoCells™ allow researchers to more efficiently screen potential drug candidates for drug transporter inhibition and phenotyping.  For companies looking to outsource their SLC Transporter Interaction Studies using Corning TransportoCells, Corning GentestSM Contract Research Services are available. 

“We are pleased to now offer a complete range of drug discovery products and services which meet and exceed the demands of our global customers. These new microplate products, coupled with our existing broad range of cell culture and bioprocess products, are a testament to our commitment to market leading drug discovery technologies, now and in the future,” said Dr. Richard Eglen, vice president and general manager, Corning Life Sciences. Eglen was recently appointed to the nine-member SLAS Board of Directors and will serve a three-year term, which began on Jan. 1.

Also at SLAS 2014, Corning will make a tutorial presentation from 2 – 2:45 p.m. PST, Tuesday, Jan. 21, in Room 28A. The session, entitled “Technology for High Throughput Screening and Drug Profiling,” will be led by Dr. David Randle and will demonstrate Corning’s broad range of products and services that support drug discovery workflows, from discovery and target identification to ADME and toxicology assays. Corning will also be making a poster presentation (poster #238), “Corning® High-Content Imaging Cyclic Olefin Copolymer (COC) Microplates Provide a Robust Tool for High Content Analysis,” from 1-3 p.m. PST, Monday, Jan. 20.

Additionally, join Corning for “Late Night with LRIG: Rapid-Fire Innovation Session” from 6:30-8:30 p.m., Monday, Jan. 20, to hear Dr. Mark Rothenberg discuss the new Corning® High-Content Screening Microplates.

Through acquisition and ongoing R&D investment, Corning now offers a more comprehensive range of premium, innovative laboratory products and solutions for a wide spectrum of life science applications. Corning’s trusted, quality brands, backed by technical expertise, provide researchers with better ways to advance their research from the beginning of their process to the end. The family of brands includes Corning®, PYREX®,  Falcon®,  Axygen®, Gosselin™ and Corning cellgro®.

To learn more about the Corning® 96- and 384-Well Spheroid Microplates, the Corning® High-Content Imaging COC Microplates, or any Corning Life Sciences products, please contact a customer service representative at 1-800-492-1110, toll free in the U.S. (+1) 1-978-442-2200 internationally; or visit .

About Corning Incorporated
Corning Incorporated ( ) is the world leader in specialty glass and ceramics. Drawing on more than 160 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences. Our products include glass substrates for LCD televisions, computer monitors and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy, and metrology.

Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.